Beruflich Dokumente
Kultur Dokumente
Presented by:
Dayang Nurazilawani binti Kassim
Tham Yuen Sin
Nurul Aqilah binti Mohd Hassan
Mohamad Haziq bin Ahmad Mazuki
Supervisor:
Prof. Dr. Norlia Abdullah
ANATOMY OF THE BREAST
• Lymphatic drainage
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
• The most common cause of breast problems; up to
30% of women suffer from benign breast disorder at
some time in their lives
• Common symptoms:
- Pain
- Breast lump
• Aim of treatment:
- To exclude cancer
- To treat any remaining symptoms
BENIGN BREAST DISORDER
CLASSIFICATION
• Congenital disorders
- Inverted nipple
- Supernumerary breast / nipples
- Non-breast disorders
- Tietze’s disease (costochondritis)
- Sebaceous cysts and other skin conditions
• Injury
• Inflammation / infection
• ANDI (alterations of normal differentiation and involution)
- Cyclical nodularity and mastalgia
- Cysts
- Fibroadenoma
• Duct ectasia / periductal mastitis
• Pregnancy-related
- Galactocele
- Puerperal abscess
BREAST CYSTS
• Benign, fluid-filled sac within the breast
• Common in perimenopausal women
• Often multiple, may be bilateral and can
mimic malignancy
• Pathophysiology:
Hormonal changes
Excess oestrogen
Fibrosis
Obstruction of duct
Cyst formation
• Clinical presentation:
- Varies in size and may be associated with pain
- Nipple discharge may be present
- Palpation: A well circumscribed, single/
multiple, smooth and mobile, oval/ round in
shape, tender
• Investigations:
- Mammogram - Ultrasound
- No further treatment
required if: Resolved
completely, fluid is not
blood stained
• Clinical presentation:
- Mostly asymptomatic and coincidentally
discovered on routine mammography
- Patients may present with a painless
palpable breast lump which is soft and
mobile
- Skin tethering or fixation are not features
of lipoma
• Investigations:
- Mammogram - Ultrasound
2. Mammogram
- >35-year-old
- Findings:
oval shaped, well- defined soft tissue densities with smooth or
lobulated margin
macrocalcification can be seen (popcorn appearance)
• Lab investigation:
(a)Mammogram
- non-specific large rounded oval or lobulated well-
circumscribed lesion with smooth margins
(b) Ultrasound
-inhomogeneous solid appearing mass
-round-like cystic spaces
• Management
(a) Wide Local Excision
(b) Simple mastectomy (for large lesion)
MASTITIS
Lactational
mastitis
Central
Mastitis (periareolar
infection)
Non- lactational
mastitis
Peripheral Non-
Lactating Abscess
LACTATIONAL MASTITIS
• Inflammation of breast in breastfeeding women
• Usually developed within first 6 weeks of breastfeeding
• Aetiological agent: Staphylococcus Aureus,
Staphylococcus Epidermidis, Streptococcus
• Predisposing factor:
(a) Cracked nipple
(b) Improper cleaning of the nipple
(c) Infection from the mouth of baby
(d) Inadequate sucking by the baby causing milk stasis
• Clinical Features :
- Painful
- Swelling
- Erythema
- Nipple crack
- Systemic symptoms: fever, malaise
- Complication: Breast abscess
• Management :
- Antibiotic therapy: Flucoxacillin/ Co-amoxiclav
- Supportive therapy: Local heat and analgesia
(NSAID) to relieve pain
- Encourage breastfeeding from the affected
site unless there is nipple discharge - to
reduce stasis of milk
- Management of bacterial abscess: aspiration/
incision and drainage
NON- LACTATIONAL MASTITIS
1. Central (Periareolar) Infection
(a) Most commonly seen in young woman (mean
age 32 year-old)
(b) Risk factor: cigarette smoke
substance in the smoke either
directly or indirectly damage the
subareolar breast duct and damage
the tissue
(c) Clinical feature:
breast pain, erythema, periareolar swelling,
nipple discharge
(d) Treatment:
Oral antibiotics
-Co-amoxiclav
-Clarithromycin + Metronidazole
Aspiration or incision and drainage (Abscess)
Total excision of affected duct (Recurrent
cases)
Lifestyle modification - stop smoking
2. Peripheral Non-Lactating Abscess
(a) Less common
(b) Associated with underlying condition such as
Diabetes Mellitus, Rheumatoid Arthritis,
Steroid Treatment
(c) Treatment:
Antibiotic therapy
Needle aspiration or incision and drainage
under local anesthesia
BREAST CARCINOMA
Overview of Breast Carcinoma
• Breast cancer is the
third most common
cancer worldwide and
is the most common
cancer in women.
• In Malaysia, October is
the Breast Cancer
Awareness Month.
Overview of Breast Carcinoma
Types of breast cancer:
Invasive (70%)
-ductal (most common)
-lobular
In-situ (30%)
-DCIS
-LCIS
Others
-Inflammatory
-Paget’s disease of the nipple
-Mucinous
-Tubular
Risk Factors of Breast Carcinoma
Risk Factor Explanation
Gender Female has higher risk than male
Lifestyle
• BMI >25 kg/m2 has increased risk
• Alcohol
Risk Factors Stratification of
Breast Carcinoma
Low Risk Moderate Risk High Risk
Reproductive factors:
Benign breast disease with atypical
Reproductive factors: - Early menarche (<12 y/o) hyperplasia
- Increasing age at first full-term - Late menopause (>55 y/o)
pregnancy (> 30 y/o) - Nulliparity
Ionising radiation
- Hormone replacement therapy
- Oral contraceptive pill usage
Carrier of BRCA1 and BRCA2 gene
Benign breast disease with proliferation mutation
without atypia
Inflamed or
scarring of duct
Indicates
inflammatory
carcinoma
Clinical
Imaging Pathology
assesment
• History • Mammogram • FNAC
• Physical • Ultrasound • Core biopsy
examination • MRI
Mammogram
Present of
microcalcification
Breast Imaging Reporting and
Data System (BIRADS)
1- no changes
2- Benign finding
3- Probably benign finding
4- Suspicious abnormality
5- Highly suggestive malignancy
6- Confirm 100% malignant changes
Ultrasound
Hypoechic
lesion
Magnetic resonance imaging (MRI)
Liver
Chest x ray
ultrasound
CT scan of
CT or MRI of
thorax and
brain
abdomen
Pathology
Fine needle aspiration cytology
• Provides cell for cytology
• Can differentiate benign and malignant tumor
• Cannot differentiate carcinoma in situ with
invasive carcinoma
Core biopsy
• Provides tissue for histology
• Can differentiate carcinoma in situ with
invasive carcinoma
• Able to detect oestrogen receptor (ER),
progesterone receptor (PR), Human epidermal
growth factor receptor(HER-2)
Sentinel lymph node biopsy
• Indication :
1. Clinically non palpable axillary lymph node
2. Unifocal tumour ≤ 3cm
Step : Radioisotope + blue dye will be inject
either under the nipple into the skin over the
cancer or around the cancer Detect by
hand-held probe or stained blue or
scintigraphy
If positive, dissect the lymph node
Treatment
Local therapy
Systemic therapy
(surgery)
Breast conserving
surgery (BCS) Chemotherapy Endocrine therapy
Mastectomy with
axillary lymph node
surgery
with/without breast
reconstruction
Neo-adjuvant
Wide local excision
and axillary lymph
node surgery,
adjuvant
radiotherapy Adjuvant
Breast conserving surgery
• The aim is to remove the cancer completely in
as small a volume of tissue as possible
• It involves excising the tumor with 1 cm
margin of macroscopically normal tissue
• It combines with SLNB or axillary clearance
• Radiotherapy must be given as an adjunct to
prevent recurrence
Indication of breast conserving surgery
• Single tumour which <4cm in diameter with
proper tumor breast ratio
• Possible to excise the tumor with tumor free
margin without disrupting the breast
cosmetically
• No contraindication for radiotherapy (ex:
pregnancy)
Modified radical mastectomy
with/without breast reconstruction
• Indication :
1. Large or multicentric tumour and mobile
axillary lymph node
2. When radiotherapy is not available/ wish
avoid radiotherapy
3. Who elect to have a mastectomy
4. When breast conservation would result to an
unacceptable cosmetic result
Treatment
Local therapy Systemic
(surgery) therapy
Breast Mastectomy
conserving Endocrine
with axillary Chemotherapy
surgery (BCS) therapy
lymph node
surgery
with/without
Wide local breast Neo-adjuvant
excision and reconstruction
axillary lymph
node surgery,
adjuvant Adjuvant
radiotherapy
Palliative
Chemotherapy
• Example regime is FAC (5-Fluoroucil,
adriamycin, cyclophosphomide) over 6 cycle
every 21 days. Others are AC
(Adriamycin,Cyclophosphomide)
• Side effects : Loss of hair, fatigue, lethargy,
nausea and vomitting,
Adjuvant Chemotherapy ( after surgery)
• Following surgery, adjuvant chemotherapy should
be offered to all women with any of the following
risk factors especially in pre-menopausal women:
1. one or more positive axillary lymph nodes
2. Estrogen receptor(ER) negative disease
3. tumor size >2cm
4. HER-2 3+
Neo-adjuvant Chemotherapy
• Given before surgery in case of operable
locally advance breast cancer
• The aim is to downsize the tumor so that
surgery can be perform
Adjuvant anti-HER2
• Targeted therapy directed against HER2
protein.
• Over-expression of HER-2 has been associated
with poorer prognosis.
• Example: Trastuzumab (Herceptin)
Endocrine therapy
Tamoxifen Aromatase inhibitor (letrozole,
anastrozole, exemestane)